Get Access
TreelipClinical Program Risk Radar
Oncology Phase 2Methodology
NCT01557959

Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Public trial-level signal summary for this oncology Phase 2 record.

Back to reportOpen ClinicalTrials.gov
Record overview

Status and phase

Status: COMPLETED

Phase: PHASE2

Sponsor: Wake Forest University Health Sciences

Condition: Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer, Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer

Signal summary

Public flags

Status signal: Low Signal

Timeline signals: stale_update_signal

Results signal: Low Signal

Operational burden: rare_population_signal | strict_eligibility_signal

Stopped reason

Context when available

No stop reason available in the current public record.